POLIVY® + R-CHP:
Superior Progression-Free Survival (PFS) vs R-CHOP1
in the ITT population (HR [95% CI]: 0.73 [0.57, 0.95], p=0.0177)
in the ITT population (HR [95% CI]: 0.73 [0.57, 0.95], p=0.0177)
in the ITT population (HR [95% CI]: 0.73 [0.57, 0.95], p=0.0177)
National Comprehensive Cancer Network® (NCCN®) recommends polatuzumab vedotin-piiq (POLIVY) + R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) as a category 1 treatment option across all stages of diffuse large B-cell lymphoma for certain* patients.2
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
National Comprehensive Cancer Network® (NCCN®) recommends polatuzumab vedotin-piiq (POLIVY) + R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) as a category 1 treatment option across all stages of diffuse large B-cell lymphoma for certain* patients.2
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
POLIVY + R-CHP is approved for 1L DLBCL, NOS or HGBL and IPI ≥2.1
*Category 1 treatment option for patients with previously untreated stage I-II (without extensive mesenteric disease) diffuse large B-cell lymphoma and smIPI score >1; Category 1 preferred treatment option for patients with previously untreated stage II (with extensive mesenteric disease) or stage III-IV diffuse large B-cell lymphoma and IPI score ≥2.
1L = first-line; CI = confidence interval; DLBCL = diffuse large B-cell lymphoma; HGBL = high-grade B-cell lymphoma; HR = hazard ratio; IPI = International Prognostic Index; ITT = intention-to-treat; NCCN = National Comprehensive Cancer Network® (NCCN®); NOS = not otherwise specified; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHP = rituximab, cyclophosphamide, doxorubicin, and prednisone; smIPI = stage-modified International Prognostic Index.
POLIVY Prescribing Information. South San Francisco, CA: Genentech, Inc.; April 2023.
POLIVY Prescribing Information. South San Francisco, CA: Genentech, Inc.; April 2023.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.1.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed January 22, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.1.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed January 22, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org.
Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842-858. doi:10.1056/NEJMra2027612
Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842-858. doi:10.1056/NEJMra2027612
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. doi:10.1182/blood-2017-03-769620
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. doi:10.1182/blood-2017-03-769620
Maurer MJ, Habermann TM, Shi Q, et al. Utility of 2-year PFS24 to predict subsequent outcomes for patients with DLBCL enrolled on randomized clinical trials: findings from a surrogate endpoint in aggressive lymphoma (SEAL) analysis of individual patient data from 5853 patients. Blood. 2018; 128:3027.
Maurer MJ, Habermann TM, Shi Q, et al. Utility of 2-year PFS24 to predict subsequent outcomes for patients with DLBCL enrolled on randomized clinical trials: findings from a surrogate endpoint in aggressive lymphoma (SEAL) analysis of individual patient data from 5853 patients. Blood. 2018; 128:3027.
Morrison VA, Shou Y, Bell JA, et al. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncol. 2019;15(9):1021-1034.
Morrison VA, Shou Y, Bell JA, et al. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncol. 2019;15(9):1021-1034.
Purdum A, Tieu R, Reddy SR, Broder MS. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist. 2019;24(9):1229-1236. doi:10.1634/ theoncologist.2018-0490.
Purdum A, Tieu R, Reddy SR, Broder MS. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist. 2019;24(9):1229-1236. doi:10.1634/ theoncologist.2018-0490.
Wang R, Roth J, Ng C, Hossain F, Li J, Masaquel A. Cost of disease progression after frontline (1L) R-CHOP in diffuse large B-cell lymphoma (DLBCL). Presented at: the American Society of Hematology Annual Meeting in Atlanta, GA; December 12, 2021. Poster presentation; Abstract 3002.
Wang R, Roth J, Ng C, Hossain F, Li J, Masaquel A. Cost of disease progression after frontline (1L) R-CHOP in diffuse large B-cell lymphoma (DLBCL). Presented at: the American Society of Hematology Annual Meeting in Atlanta, GA; December 12, 2021. Poster presentation; Abstract 3002.
Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020; 135(23): 2041-2048.
Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020; 135(23): 2041-2048.
Kanas G, Ge Wenzhen, Quek R, et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025. Leuk Lymphoma. 2021;63()1:54-63.
Kanas G, Ge Wenzhen, Quek R, et al. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025. Leuk Lymphoma. 2021;63()1:54-63.
Harrysson S, Eloranta S, Ekberg S, et al. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021;11(1):9.
Harrysson S, Eloranta S, Ekberg S, et al. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021;11(1):9.
Shi X, Liu X, Li X, et al. Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and international prognostic index: a multicenter retrospective study. Front Oncol. 2021;11:754964.
Shi X, Liu X, Li X, et al. Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and international prognostic index: a multicenter retrospective study. Front Oncol. 2021;11:754964.
Iacoboni G, Zucca E, Ghielmini M, Stathis A. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Ann Oncol. 2018;29(5):1120-1129. doi:10.1093/annonc/mdy113
Iacoboni G, Zucca E, Ghielmini M, Stathis A. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Ann Oncol. 2018;29(5):1120-1129. doi:10.1093/annonc/mdy113
Fanale D, Bronte G, Passiglia F, et al. Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option? Anal Cell Pathol. 2015;690916.
Fanale D, Bronte G, Passiglia F, et al. Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option? Anal Cell Pathol. 2015;690916.
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351-363.
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351-363.
Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74-87.
Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74-87.
Poletto S, Novo M, Paruzza L, et al. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev. 2022;110:102443
Poletto S, Novo M, Paruzza L, et al. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev. 2022;110:102443
Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. US Food and Drug Administration. December 2018. Accessed February 23, 2024. https://www.fda.gov/media/71195/download
Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. US Food and Drug Administration. December 2018. Accessed February 23, 2024. https://www.fda.gov/media/71195/download
Data on File. South San Francisco, CA; Genentech, Inc. 2023.
Data on File. South San Francisco, CA; Genentech, Inc. 2023.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma - study protocol. N Engl J Med. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma - study protocol. N Engl J Med. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. doi:10.1200/JCO.2013.54.8800
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. doi:10.1200/JCO.2013.54.8800
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.